CLASS 3 RECALL - KOLANTICON GEL 500ML

Intrapharm Laboratories Ltd has received a number of complaints that the product consistency is lumpy. The investigation has confirmed through review of the retained samples that the consistency of the complaint samples are similar and the retained samples for this batch show the same homogeneity issue

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-intrapharm-laboratories-ltd-kolanticon-gel-500ml-el-21-a-slash-01?utm_medium=email&utm_campaign=govuk-notifications&utm_source=1c3cadd1-c259-4e77-b3e8-c13faf584fe2&utm_content=immediately  

For more information or medical information queries, please contact: medinfo@intrapharmlabs.com or telephone +44 (0)330 1359 437.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

If you have any questions, then please contact your local Service Centre Customer Services team.

FIELD SAFTEY NOTICE - BD SYRINGES AND NEEDLES

BD has become aware that when syringes and needles are used for intraocular injections, the potential exists for “floaters” in patients’ eyes which are believed to be due to silicone. (Note: Syringes and needles manufactured by BD have silicone applied to the inside of the barrels to provide lubrication for the plunger stopper, allowing it to move easily). The potential hazard is deposition of silicone oil (SO) droplets in the vitreous.  The potential harm could be symptomatic “floaters” in the patient’s field of vision which, normally, are tolerable and resolve over a few months.  However, if sufficiently bothersome, floaters may lead to a vitrectomy for their removal

MHRA drug alert link: N/A              

This field safety notice is Advisory only so Alliance Healthcare are not accepting stock returns.

Should you have any questions or experience any issues associated with the product or issue described in this Field Safety Notice, please contact BDUKFieldAction@bd.com. BD has notified the appropriate regulatory agencies of these actions.

COMPANY-LED DRUG ALERT - RESPREEZA 1,000 MG POWDER AND SOLVENT FOR SOLUTION FOR INFUSION

CSL Behring UK Ltd is recalling the below batches of Respreeza 1,000 mg powder and solvent for solution for infusion (EU/1/15/1006/001) due to a manufacturing deviation that occurred during the filling process. There is a risk of potential microbial contamination due to the failure of the HEPA filters at the manufacturing site and the batches are being recalled as a precautionary measure. This product is only supplied to Pharmacies and/or Hospitals Pharmacies and not to wholesale, via our 3PL partner Alloga UK Ltd

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/company-led-medicines-recall-respreeza-1000-mg-powder-and-solvent-for-solution-for-infusions-eu-slash-1-slash-15-slash-1006-slash-001?utm_medium=email&utm_campaign=govuk-notifications&utm_source=ea5d64be-6beb-4a4b-b8a9-a24edc5aeea8&utm_content=immediately              

Alliance do not stock this product and therefore we are not accepting stock returns.

Company Contact for medical information enquiries

For medical information enquiries, please contact: Jo Heaton (Head of Medical Affairs UK & Ireland, Commercial Operations United Kingdom) CSL Behring UK Ltd by emailing: Jo.Heaton@cslbehring.com

Company Contact for stock enquiries

For stock information enquiries, please contact: Karien Pietersen (Head of Quality) CSL Behring UK Ltd by emailing: Karien.pietersen@cslbehring.com

CLASS 2 RECALL - Sodiofolin 50mg/ml Solution for Injection 100mg/2ml

Further to Drug Alert EL (20)A/52 issued on 11 November 2020, medac Pharma LLP is recalling further batches of products following inspection of vials showing hairline damage to the shoulder of the vials. So far, the company has not received any reports of damage for marketed products. However, as this defect may impact on the sterility of the product, the below batches are being recalled as a precautionary measure

MHRA Drug Link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-medac-gmbh-t-slash-a-medac-pharma-llp-sodiofolin-50mg-slash-ml-solution-for-injection-100mg-slash-2ml-pl-11587-slash-0005-el-20-a-slash-61?utm_source=84015acc-7689-472c-92fe-db322a8d4537&utm_medium=email&utm_campaign=govuk-notifications&utm_content=immediate

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

For more information or medical information queries, please contact info@medacpharma.co.uk or telephone 01786 458086.

COMPANY-LED DRUG ALERT - INSTANYL 100MCG SINGLE DOSE

Takeda UK Limited is recalling the below batch of Instanyl 100mcg nasal spray solution (EU/1/09/531/015) due to the observation of cracked vials during inspection of the bulk vials and release testing of the finished products. So far, the company has not received any reports of damage for the marketed products. However, due to the low potential for breaking or cracking of the glass vial, which is contained within the plastic actuator casing and a potential risk of microbial contamination, the above batch is being recalled as a precautionary measure

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/company-led-medicines-recall-instanyl-100mcg-nasal-spray-solution-eu-slash-1-slash-09-slash-531-slash-015?utm_medium=email&utm_campaign=govuk-notifications&utm_source=a6ea9305-5a64-4dd6-ae86-912f9bbbe915&utm_content=immediately         

Alliance have not supplied this product and therefore we are not accepting stock returns.

Company Contact for medical information enquiries

For medical information enquiries, please contact: Takeda UK Limited by emailing medinfoemea@takeda.com

Company Contact for stock enquiries

Remaining stock of these batches should be quarantined and returned to Takeda for replacement stock where available.

For stock information enquiries, please contact: Alloga UK by emailing allogaUK.credit.claims@alloga.co.uk

Company-Led drug alert Sodium Chloride 0.9% Solution For Injection

Title:  Company-Led drug alert Sodium Chloride 0.9% Solution For Injection
Class type: Company-Led drug alert

Copy: Fresenius Kabi Ltd is recalling the below batch of Sodium chloride 0.9% Solution for injection (PL 08828/0178) which has a polish labelled ampoule within some of the cartons. As this does not impact the full batch, as a precautionary measure Fresenius Kabi are recalling all packs from this batch number. The outer carton is correct and includes the correct patient information leaflet in the English language. The ampoules are the correct composition and specifications as the UK licensed material, however during manufacture the incorrect ampoule label was used. The affected batch is being recalled and all stock will be replaced by corrected stock from Fresenius Kabi Limited.

The affected products' details are as follows:

Alliance do not stock this product we are not accepting stock returns.

For stock information enquiries, please contact: Fresenius Kabi Ltd customer services centre Email: Customer.Services-UK@Fresenius-Kabi.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

Field Safety Notice - Voluntary Recall Unisex Patterned Sock C1 Med

L&R Medical Uk Ltd (Pway)is recalling the above batches of products as a Field Safety Notice - Voluntary Recall

The affected products' details are as follows:

This is a FSN voluntary recall and Alliance will be accepting stock returns.

For further information, please contact L&R Medical on 08450 606707

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

CLASS 2 RECALL - ZERBAXA 1G/0.5G POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION

Merck Sharp & Dohme Limited is recalling the below batches due to the presence of Ralstonia pickettii in recent batches that were manufactured. The below batches are recalled as a precautionary measure whilst investigations into the microbiological quality of the distributed products are underway

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-merck-sharp-and-dohme-limited-zerbaxa-1g-slash-0-dot-5g-powder-for-concentrate-for-solution-for-infusion-el-20-a-slash-60?utm_source=22cd61e8-ab02-4646-bc21-a8c64c009886&utm_medium=email&utm_campaign=govuk-notifications&utm_content=immediate     

Please note that Alliance Healthcare do not stock and we are not accepting stock returns.

For stock control enquiries please contact customerservice.msduk@msd.com

Phone number: 01992 452094

For more information or medical information at medicalinformationuk@msd.com

Phone number: 01992 467272

Class 4 Drug Alert (Caution in use only) Co-Careldopa 25mg/100mg tablets

Fairmed Healthcare GmbH has informed us of a discrepancy on the product packaging for some batches. The discrepancy relates to the incorrect spelling of one of the active pharmaceutical ingredients printed on one side of the packs in error.

The affected products' details are as follows:

This is a caution in use only we are not accepting stock returns.

For more information or medical information queries, please contact:

Fairmed Healthcare GmbH

Dorotheenstraße 48, 22301

Hamburg, Germany, Quality Assurance Department

or via email on QA Manager: l.rozikova@fair-med.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

Class 4 Drug Alert (Caution in use only) Perindopril Erbumine 2mg, 4mg & 8mg Tablets

Generics [UK] Limited t/a Mylan have informed us that the Patient Information Leaflet (PIL) within the packs for the products listed above is missing relevant important safety information.

The affected products' details are as follows:

This is a caution in use only we are not accepting stock returns.

For more information or medical information queries, please contact: Generics [UK] Limited t/a Mylan Medical Information Direct Line +44 (0)1707 853 000 select option 1, Customer Care direct line +44 (0)1707 853 000 select option 2 or via Medical Information e-mail info@mylan.co.uk

Recipients of this Drug Alert should bring it to the attention of relevant contacts.